Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Expert Opin Biol Ther
; 23(3): 293-304, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2300215
ABSTRACT
BACKGROUND:
Vedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ. RESEARCH DESIGN ANDMETHODS:
Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity. Achievement and maintenance of clinical remission during the follow-up, and safety were the primary endpoints.RESULTS:
729 patients (475 with UC and 254 with CD), median follow-up of 18 (IQR 6-36) months, were enrolled. Clinical remission at the 6th month of treatment was achieved in 488 (66.9%) patients (74.4% in CD vs 62.9% in UC, p<0.002) while, during the follow-up, no difference was found (81.5% in the UC group and 81.5% pts in the CD group; p=0.537). The clinical remission at the 6th month of treatment (p=0.001) and being naïve to biologics (p<0.0001) were significantly associated with prolonged clinical remission. The clinical response was significantly higher in UC (90.1%) vs CD (84.3%) (p=0.023), and surgery occurred more frequently in CD (1.9% in UC vs 5.1% in CD, p=0.016).CONCLUSION:
We found differences when using VDZ in UC vs CD in real life. These parameters can help the physician predict this drug's longterm efficacy.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Enfermedades Inflamatorias del Intestino
/
Colitis Ulcerosa
/
Enfermedad de Crohn
Tipo de estudio:
Estudio de cohorte
/
Estudio experimental
/
Estudio observacional
/
Estudio pronóstico
Límite:
Humanos
País/Región como asunto:
Europa
Idioma:
Inglés
Revista:
Expert Opin Biol Ther
Asunto de la revista:
Biologia
/
Terapeutica
Año:
2023
Tipo del documento:
Artículo
País de afiliación:
14712598.2023.2185510
Similares
MEDLINE
...
LILACS
LIS